CXL: Corneal Collagen Cross Linking

A new therapeutic approach for the treatment of keratoconus is the interconnection of the corneal collagen (Corneal Cross Linking, CXL) with the use of riboflavin (vitamin B2) and Ultraviolet irradiation A. The aim is the improvement of the resistance and rigidity of the cornea -stiffening effect- that ceases the development of keratoconus. IVO in this moment is concerned as the world’s avant-garde in the application of this treatment and constitutes a point of reference in CXL treatment.

A one-time application of riboflavin solution is administered to the eye and is activated by illumination with UV-A light for approximately 30 minutes.    The riboflavin causes new bonds to form across adjacent collagen strands in the stromal layer of the cornea, which recovers and preserves some of the cornea's mechanical strength. The corneal epithelial layer is generally removed in order to increase penetration of the riboflavin into the stroma.The duration of the treatment is one hour and it is painless due to the use of local anesthaetic drops. In the end of the treatment, a bandage contact lens is placed in the eye which remains from 4 to 6 days.